FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, in particular to a monoclonal antibody which specifically binds to an auxiliary protein of the human interleukin-1 (IL1RAP) receptor. Also disclosed is a conjugate containing said antibody, a pharmaceutical composition containing said antibody. Disclosed are use of said antibody and said conjugate for treating or diagnosing diseases associated with IL1RAP, a method of treating or diagnosing with said antibody.
EFFECT: invention provides effective treatment of diseases associated with IL1RAP.
144 cl, 10 ex, 5 tbl, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| ANTIBODIES AGAINST HUMAN VSIG4 AND APPLICATION THEREOF | 2019 |
|
RU2776638C1 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| IMPROVED ANTIGEN-BINDING RECEPTORS | 2018 |
|
RU2825816C2 |
| ANTIBODY TO HUMAN CD73 | 2017 |
|
RU2754058C2 |
